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Abstract
To determine if nuclear factor-κB (NF-κB) activation may be a key factor in lung inflammation and
respiratory dysfunction, we investigated whether NF-κB can be blocked by intratracheal
administration of NF-κB decoy oligodeoxynucleotides (ODNs), and whether decoy ODN-
mediated NF-κB inhibition can prevent smoke-induced lung inflammation, respiratory dysfunction,
and improve pathological alteration in the small airways and lung parenchyma in the long-term
smoke-induced mouse model system. We also detected changes in transcriptional factors. In vivo,
the transfection efficiency of NF-κB decoy ODNs to alveolar macrophages in BALF was measured
by fluorescein isothiocyanate (FITC)-labeled NF-κB decoy ODNs and flow cytometry post
intratracheal ODN administration. Pulmonary function was measured by pressure sensors, and
pathological changes were assessed using histology and the pathological Mias software. NF-κB and
activator protein 1(AP-1) activity was detected by the electrophoretic motility shift assay (EMSA).
Mouse cytokine and chemokine pulmonary expression profiles were investigated by enzyme-linked
immunosorbent assay (ELISA) in bronchoalveolar lavage fluid (BALF) and lung tissue homogenates,
respectively, after repeated exposure to cigarette smoke. After 24 h, the percentage of transfected
alveolar macrophages was 30.00 ± 3.30%. Analysis of respiratory function indicated that
transfection of NF-κB decoy ODNs significantly impacted peak expiratory flow (PEF), and
bronchoalveolar lavage cytology displayed evidence of decreased macrophage infiltration in airways
compared to normal saline-treated or scramble NF-κB decoy ODNs smoke exposed mice. NF-κB
decoy ODNs inhibited significantly level of macrophage inflammatory protein (MIP) 1α and
monocyte chemoattractant protein 1(MCP-1) in lung homogenates compared to normal saline-
treated smoke exposed mice. In contrast, these NF-κB decoy ODNs-treated mice showed
significant increase in the level of tumor necrosis factor-α(TNF-α) and pro-MMP-9(pro-matrix
metalloproteinase-9) in mice BALF. Further measurement revealed administration of NF-κB decoy
ODNs did not prevent pathological changes. These findings indicate that NF-κB activation play an
important role on the recruitment of macrophages and pulmonary dysfunction in smoke-induced
chronic lung inflammation, and with the exception of NF-κB pathway, there might be complex
mechanism governing molecular dynamics of pro-inflammatory cytokines expression and structural
changes in small airways and pulmonary parenchyma in vivo.
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Introduction
Extensive exposure to cigarette smoke is a principal risk
factor associated with chronic obstructive pulmonary dis-
ease (COPD). COPD is a complex inflammatory disease
involving numerous inflammatory cell types, which have
the capacity to release multiple inflammatory mediators.
An increase in expression of many of these mediators
translates to activation of an inflammatory cascade
involving cytokines, chemokines, growth factors,
enzymes, receptors, and adhesion molecules [1-4]; spe-
cific to COPD are increased levels of tumor necrosis fac-
tor-α (TNFα), interferon-γ(IFNγ), interleukin-8(IL-8),
macrophage inflammatory protein 1α(MIP-1α), mono-
cyte chemoattractant protein 1(MCP-1), GROα, and
matrix metalloproteinase(MMP)-9 [1-4].
NF-κB is a family of critical transcription factors regulating
many cytokines, including IL-8, IL-6, TNF-α, GM-CSF,
MIP-1, and MCP-1 [5], as well as MMP-9 expression [6].
In the past few years, five mammalian NF-κB family mem-
bers have been identified and cloned [7-9]. These include
NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65),
RelB, and c-Rel. In resting cells NF-κB is retained in the
cytoplasm due to inhibitory protein (I-κB) binding. When
the cell is appropriately stimulated, I-κB degradation
results in the ability of NF-κB to recognition nuclear local-
ization signals of p65, thus it is rapidly transported into
the nucleus where it binds to specific κB recognition ele-
ments in the promoters of target genes [10]. Chronic
exposure to cigarette smoke causes cellular oxidative
stress, a key feature in smoking-induced lung inflamma-
tion [11-13], and oxidative stress (particularly hydrogen
peroxide) can enhance the DNA binding activity of NF-κB
[14].
It has been demonstrated in humans and animal models
that smoke-induced chronic pulmonary inflammation is
associated with increased NF-κB activity in lung cells.
Enhanced NF-κB activation has been observed in bron-
chial biopsies from smokers, macrophages from COPD
patients and in guinea pigs exposed to cigarette smoke,
with a subsequent increase in IL-8 release [15-17]. During
the past few years, tremendous progress has been achieved
in our understanding on how intracellular signaling path-
ways are transmitted in either a linear or a network man-
ner leading to the activation of NF-κB and airway
inflammation control [18-20]. However, a detailed role in
long-term smoke-induced inflammation and the impact
of NF-κB inhibition on histology and airflow obstruction
has yet to be determined. Therefore, we have used NF-κB
decoy ODNs to block NF-κB activity in mouse lung during
long-term smoke exposure. It is well known that transfec-
tion of cis-element double-stranded oligodeoxynucle-
otides (decoy) has been identified as a powerful tool in a
new class of anti-gene strategies for gene therapy and
research [21]. Transfection of decoys corresponding to a
specific cis sequence results in the attenuation of endog-
enous cis-elements, and subsequent modulation of gene
expression [21,22].
We hypothesized that in the long-term smoke-induced
mouse model double-stranded ODNs decoy to NF-κB
would suppress the pulmonary expression levels of
inflammation-related genes and MMP-9/TIMP-1 gene
that may play a role in the development of emphysema.
The other purpose of this study was to assess the potential
of NF-κB decoy ODNs to histological influence. Based on
the evidence that early structural changes may occur in
peripheral airways of smokers before COPD [23], we fur-
ther measured small-airway changes. Since NF-κB and AP-
1 may regulate each other [24], both of NF-κB and AP-1
activities were measured after intratracheal administration
of NF-κB decoy ODNs in 92 day smoke-induced mice.
Therefore, the present study was performed to determine
the effects of NF-κB decoy ODNs on lung inflammation




Double-stranded NF-κB decoy ODNs containing the con-
sensual NF-κB binding site (5'-GGGATTTCCC-3') were
generated using equimolar amounts of single-stranded
sense and antisense phosphorothioate-modified ODNs
(sense strand: 5'-CCT TGA AGG GAT TTC CCT CC-3') as
previously described [25]. Briefly, synthetic single-
stranded ODNs were dissolved in sterile STE buffer (10
mM Tris, 1 mM EDTA, 100 mM NaCl, pH 8.0), purified by
PAGE and quantified by SDS gel electrophoresis (AuGCT
company, Beijing, China). Single-stranded ODNs were
then annealed for 3 h, during which time the temperature
was reduced from 94°C to 25°C. Double-stranded scram-
bled ODNs were used as negative controls (sense strand:
5'-TTG CCG TAC CTG ACT TAG CC-3') [25]. In the flow
cytometry experiment, the sense and antisense NF-κB
decoys ODN were modified with FITC labels at both the
5'and 3'end.
Animals
Male C57/BL6 mice (6–8 weeks of age, 20 ± 0.5 g, Beijing
University Animal Center, Beijing, China) were divided
into 3 groups, treated for 92 days smoke exposure and
started intratracheal instillation on 52 days, administered
every 10 days, a total of 4 times: 1 decoy group (n = 8):
smoke-exposed followed by intratracheal instillation of
NF-κB decoy ODNs (15 nmol in 30 μl of STE buffer/
mouse); and negative controls 2 NS group (n = 8): smoke-
exposed followed by intratracheal instillation of sterile
normal saline (0.9%NS, 30 μl/mouse); and 3 Scr group (n
= 8): smoke-exposed followed by intratracheal instillationRespiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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of scrambled ODNs (15 nmol in 30 μl of STE buffer/
mouse). In order to recognize pulmonary function before
intratracheal instillation, an additional test has been
done, in which 20 mice were divided into 2 groups and
treated for 52 days 4 sham group (n = 10): air exposure; 5
smoke-exposed group (n = 10): smoke exposure. These
time points were chosen from previous data generated by
our group [26,27].
In experiments aimed at NF-κB decoy localization, intrat-
racheal administration to smoke-exposed mice (for 52
days) was performed with FITC-labeled ODNs after 3 h,
24 h, 3 days and 7 days. All animal experimentation was
approved by the Local Ethical Committee of Peking Uni-
versity, China.
Chronic exposure to cigarette smoke
Mice were whole-body exposed to cigarette smoke gener-
ated from commercial cigarettes in 300 L inhalation
chambers (Derby, USA. Tar = 13 mg, cotinine = 1.2 mg,
CO = 15 mg per cigarette). Actual smoke generation
method was designed by Masanori Nishikawa, as
described previously [16]. The exposure regime consisted
of two sessions of 5 cigarettes/hr, interrupted by a 10 min
rest period. The exposure regime was conducted twice
daily with a minimal four hour interval between sessions,
6 days/week. Carbon monoxide concentration was ranged
between10% and 12% after exposure [28], and the mice
appeared grossly normal during the entire experimental
period. Chamber concentrations of CO were 400–501
ppm (measured by Infrared Gas Analyzer, MODEL GXH-
3050A) and particulates (PM10) were 7.88–8.28 mg/m3
(measured by Respirable Aerosol Mass Monitor, MODEL
3511). Animals were maintained on a 12 h light/dark
cycle with free access to conventional laboratory food and
water. Mice were sacrificed at 24 hour after the last expo-
sure regime.
Respiratory function
After 52 or 95 days of smoke exposure, mice were anaes-
thetized by intraperitoneal injection with 1% sodium
pentobarbital, and then intubated endotracheally using
improved scalp needles. Respiratory function was meas-
ured using an Animal Ventilator (Biolab) connected to a
pressure sensor. Peak inspiratory flow (PIF) and peak
expiratory flow (PEF) were measured, and data were ana-
lyzed using Chart 4.1 software.
Bronchoalveolar lavage cytology, and cytokine assays
On day 95 of the smoke exposure regime, after exsanguin-
ation by severing the abdominal aorta, mouse lungs were
sequentially lavaged twice with 0.5 ml of Hank's balanced
salt solution (HBSS). Recovered aliquots of BALF were
pooled. Bronchoalveolar lavage (BAL) cells were pelleted
by centrifugation at 1,000 rpm for 8 min. Cell differentials
were performed on cytospin preparations stained with
Wright-Giemsa, and a total of 200 cells were counted.
Supernatant was stored at -80°C. Supernatant TNF-α and
IL-6 concentrations were measured using a commercially
available ELISA kit (Jingmei Company, Shenzhen, China)
according to the manufacturer's specifications. The con-
centration of pro-MMP-9 was detected in the supernatant
of BALF as a commercial kit for MMP-9 was not available
[29]. Pro-MMP-9 and TIMP-1 levels were detected using
ELISA kits (R&D systems, catalog number: MMP900,
MTM100, respectively). The detection limit of TNF-α, IL-
6, pro-MMP-9 and TIMP-1 were 7 pg/ml, 4 pg/ml, 3 pg/ml
and 1.4 pg/ml, respectively.
Tissue Processing
Lungs were excised from mice, and the right lobe was tied
off, harvested, washed with 4°C PBS solution, weighed
and snap-frozen in liquid nitrogen. The left lobe was
inflated with 0.25 ml of 4% paraformaldehyde and
immersed in fresh 4% paraformaldehyde for 12 h. Tissues
were embedded in paraffin and stained with hematoxylin
and eosin (H&E).
Preparation and analysis of lung homogenates for 
chemokine determination
MCP-1 and MIP-1α concentrations were measured in
lung homogenates collected from 95 day smoke-exposed
mice. The nitrogen-snap frozen portion of the right lung
was cut into small pieces and placed in 4°C PBS solution
at 4 ml/g [30], and homogenized on ice (homogenizer:
Ingenieurbüro CAT. M. Zipperer GmbH, Germany) for 20
sec at 6,000 rpm three times. Homogenates were centri-
fuged at 10,000 × g at 4°C and stored at -80°C until MCP-
1 and MIP-1α levels could be determined by FlowCy-
tomix (BMS8440FF, Bender MedSystems). The limitaton
of detection of MCP-1 and MIP-1α concentration were 50
pg/ml and 17 pg/ml, respectively.
Morphologic and Morphometric Analyses
Intra-alveolar macrophages from H&E stained lung sec-
tions in the terminal bronchiole region were counted at
400× magnification by two independent observers in a
blind study. Results were expressed as the number of mac-
rophages/mm2 [31].
Quantification of airspace enlargement was determined
by mean linear intercept (Lm) ([32-36]) and mean alveo-
lar surface (Am). The measurement of Lm was performed
by using a 100×100 μm grid that was randomly posi-
tioned in the lung. The length of each grid line, divided by
the number of alveolar intercepts, yielded the average dis-
tance between alveolated surfaces, or the Lm. The same
image was used to measure the Am. An alveolus or air-
space is defined as the space surrounded by the alveolar
wall, which in the case of an alveolus opening into a ductRespiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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ends at the mouth of the alveolus. The surface of an air-
space cross-section was calculated and divided by the
number of alveoli to obtain the Am.
The destruction of alveolar walls was quantified by the
destructive index (DI) [32]. Briefly, a grid with 42 hairline
crosses was superimposed on the lung field. Structures
lying under the cross-points were classified as normal (N)
or destroyed (D) alveolar and/or duct spaces. Points fall-
ing over other structures, such as duct walls, alveolar
walls, etc., were not considered in the calculations. The DI
was calculated using the following formula:
Analysis of small airways fibrosis and inflammation
Masson trichrome stain was used on consecutive tissue
sections as a further means to identify fibroblasts and was
carried out using Masson trichrome staining Kit (BASO
Co., Tai wan) according to the manufacturer's instruction.
Lung sections were processed for Masson's trichrome
staining to detect collagen and elastin, and analyzed by
two separate pathologists in a blinded fashion. Small air-
way fibrosis and inflammation scores were determined as
described before [37].
Flow cytometry
Localized FITC-labeled NF-κB decoys in macrophages
were detected in BALF collected from 52 day smoke-
exposed mice after FITC-labeled ODNs or 0.9% NS
administration at 24 h, 3 days and 7 days. BALF cells were
harvested by sequentially lavaging mouse lungs twice with
0.5 ml of HBSS containing 2 mM EDTA and were assayed
for non-vitality by staining with 0.4% trypan
blue(Sigma). Then the cells were pelleted by centrifuga-
tion at 800 rpm for 8 min, differentiated as described
above and filtered through nylon mesh prior to flow
cytometry analysis. Cells were incubated (for 30 min on
ice in PBS containing 2% Bovine Serum Albumin, 0.1%
Sodium azide) with either PE-conjugated anti-mouse F4/
80 (Serotec, MCA497PE) or PE-conjugated anti-mouse
IgG antibody as a isotype control (BD Pharmin-
gen,553989). Cells were washed, fixed with paraformal-
dehyde (0.25%), and analyzed using a FACSCalibur (BD
Biosciences, San Jose, CA, USA).
Nuclear Protein Extraction
Fresh snap-frozen mouse lung tissue was weighed, cut
into small pieces, and homogenized directly in Cytoplas-
mic Extraction Reagent I (Pierce, 78833). The mix solu-
tion was vortexed vigorously on the highest setting for 15
sec to resuspend the cell pellet, then incubated on ice for
10 min. Ice-cold Cytoplasmic Extraction Reagent II (11
ml) was added to the mix solution, vortexed for 5 sec on
the highest setting and incubated on ice for 1 min. The
mix solution was centrifuged for 5 min at 16,000 × g, and
the supernatant was collected in a clean pre-chilled tube.
The nuclei pellet was resuspended on ice in 100 μl of ice-
cold Nuclear Extraction Reagent, and vortexed for 15 sec
every 10 min for 40 min. The sample tube was centrifuge
at 16,000 × g for 10 min, and the supernatant (nuclear
extract) was collected in a clean pre-chilled tube and
stored at -80°C.
Electrophoretic Motility Shift Assay
Binding reactions were established in 20 μl of binding
buffer from the Pierce LightShift Chemiluminescent
EMSA Kit (Pierce,20148) using 5 μg of nuclear extract pro-
tein per reaction for the consensus probe 5'-biotin
labeled: NF-κB 5'-AGT TGA GGG GAC TTT CCC AGG C-
3'; AP-1 5'-CGC TTG ATG AGT CAG CCG GAA-3'. Sam-
ples were electrophoresed through a 5% polyacrylamide
gel for 50 min at 4°C and then transferred to a positively
charged nylon membrane for 30 min. DNA was UV cross
linked to the membrane, and the membrane was blocked
for 15 min by incubation in LightShift Blocking Buffer
with gentle shaking. The membrane was then incubated
in conjugate/blocking buffer solution for 15 min, washed
4 times for 5 min each in 10 ml LightShift Substrate Equi-
libration Buffer, followed by incubation in Washing
Buffer for 5 min with gentle shaking a total of 4 times.
Electrophoretic mobility shifts were visualized using
enhanced chemiluminescence solution (Pierce, 20148).
The binding bands and probe were analyzed using Kodak
software.
Protein Assay
Protein concentrations in lung homogenates were deter-
mined using the bicinchoninic acid (BCA) method.
Statistical Analysis
All values given represent mean ± standard deviation
(STD). Nonparametric Mann-Whitney U-test was used to
assess the statistical significance of differences between
the groups. Correlations between the BAL analysis data
and the MCP-1, MIP-1α levels were assessed with the non-
parametric Spearman correlation test. For each analysis, P
values less than 0.05 were considered to be statistically
significant. Statistical analyses were performed by using
the Statistical Package for the Statistical Analysis System
8.1(SAS, Cary, NC, USA).
Results
Respiratory function was unaltered after 52 days of smoke 
exposure
Respiratory function in the smoke-exposed mouse group,
as measured with an animal ventilator and connected
pressure sensor, was not affected after 52 days of exposure
to smoke when compared to sham controls, as illustrated
in Table 1.
DI D D N =+ × /( ) 100Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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Administration of NF-κB decoy ODNs intratracheally 
reduced NF-κB activity in the lungs after 92 days smoke 
exposure
The lungs of 92 day smoke-exposed mice were examined
for evidence of an NF-κB decoy ODNs-mediated reduc-
tion in NF-κB activation in the lungs. Nuclear extracts pre-
pared from whole lung of normal saline (NS) or
scrambled ODNs (Scr) intratracheally instillated mice
demonstrated strong NF-κB binding activity, as assessed
by EMSA (Fig. 1A). As expected, a weak NF-κB-binding
activity was observed in whole lung extracts of mice
treated with NF-κB decoy ODNs. In contrast, AP-1 bind-
ing activity was not significantly changed by NF-κB decoy
ODNs administration (Fig. 1B).
NF-κB decoy ODNs were capable of entry into alveolar 
macrophages on day 52 of smoke exposure
To show that whether decoy-mediated NF-κB inhibition
was sufficient to induce cell non-vitality of BALF cells in
52 day smoke-induced mice, we examined using trypan
blue staining at 24 hour after treatment with NF-κB decoy
ODNs or normal saline (NS) as a control. The rates of
non-vitality cells in BALF were similar to that of NS-
treated animals (Table 2). Thus, our results show that
treatment of 52 day smoke-induced mice with NF-κB
decoy ODNs did not impact on cell survival in BALF.
To localize NF-κB decoy ODNs in vivo, 52 day smoke-
exposed mice were administrated FITC-labeled ODNs
intratracheally. After 3 h, 24 h, 3 days, and 7 days cells col-
lected from BALF were examined for FITC positivity by
flow cytometry; alveolar macrophages were labeled as F4/
80. Prior to flow cytometry analysis, cell differential was
determined using cytospin preparations stained with
Wright-Giemsa, and a total of 200 tabulated cells. We
determined that alveolar macrophages in BALF consti-
tuted over 95% of total cells (Table 3). In cells collected 24
h after instillation, an observed peak depicted that 30.00
± 3.30% of the FITC signal was located in macrophages
(F4/80)(Fig. 2G and Fig. 2B), which after 7 days persisted
at 9.00 ± 0.93% (Fig. 2G and Fig. 2D). Macrophages
labeled F4/80 (an transmembrane protein, the best
marker for mature macrophages) from BALF were
assessed for PE (marked F4/80) and FITC positivity
(marked NF-κB decoy ODNs) using flow cytometry. The
data analysis was the compilation of quadrant statistics.
The co-stained cells (F4/80+, FITC-ODNs+) were showed
by R2 rectangular gating regions. The percentage in the R2
rate indirectly reflected transfection efficiency of NF-κB
decoy ODNs to the mature macrophages in vivo.
NF-κB decoy ODNs attenuated macrophage aggregation 
in smoke-induced chronic inflammation, improved lung 
function, and reduced MIP-1α and MCP-1 expression
To demonstrate that the impact of NF-κB decoy ODNs on
smoke-induced chronic inflammation, a series of experi-
ments were performed. We analyzed whether intratra-
Table 1: Respiratory Function in Cigarette Smoke-Exposed Mice 
(persistent exposure to smoke for 52 days) and Sham Mice 
(exposure to air).
Test Exposure MEAN ± STD(L/S) Pr > Chi-Square
PIF sham 1.70 ± 0.67 0.7393
smoke 1.76 ± 0.39
PEF sham 7.09 ± 0.39 0.9558
smoke 7.07 ± 0.24
The data were expressed as means ± STD and analyzed by using the 
Mann-Whitney U-test. Statistical significance was accepted at P < 
0.05.PIF: peak inspiratory flow; PEF: peak expiratory flow. n = 10–15/
group.
Demonstration of the impact of local administration of decoy  ODNs on NF-κB activation in the lungs of 92 day smoke- exposed mice Figure 1
Demonstration of the impact of local administration 
of decoy ODNs on NF-κB activation in the lungs of 92 
day smoke-exposed mice. Normal saline (NS), NF-κB 
decoys ODNs (Decoy) or scrambled ODNs (Scr) were 
administered by intratracheal instillation on day 52 in smoke-
exposed mice. Nuclear protein extracts were prepared from 
whole lung and assessed for NF-κB DNA-binding activity by 
electrophoretic mobility shift assay (EMSA). (A) A represent-
ative non-autoradiograph of EMSA analysis of level of NF-κB 
in the nuclear fraction using biotin detection. (B) A repre-
sentative of the EMSA analysis of level of AP-1 in the nuclear 
fraction by non-autoradiograph.
Table 2: Percentage of death cells in the BALF of NS-treated 
(NS) and NF-κB decoy-treated (Decoy) mice after 24 hours with 
smoke exposure for 52 days.
Treatment Non-viable cells %
NS 4.32 ± 3.93
Decoy 5.56 ± 5.53
Pr > Chi-Square 0.6579
All data are expressed as means ± STD and analyzed by using the 
Mann-Whitney U-test in two groups of mice. Statistical significance 
was accepted at P < 0.05. n = 3/group.Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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cheal delivery of NF-κB decoy ODNs could affect smoke-
induced macrophage influx, some macrophage-related
chemokines and pro-inflammatory cytokines expression,
lung function, and cell number in BALF. After smoke
exposure for 92 days, macrophage accumulation in the
alveolar space was observed in normal saline (NS) and
scrambled ODNs (Scr) mice. Treatment with NF-κB decoy
ODNs resulted in a reduction in alveolar macrophage
accumulation in the alveoli (Fig. 3A). The number of mac-
rophages is tabulated in Fig 3B.
Airway inflammation was evaluated in the BALF. Total cell
and macrophage count in the BALF recovered from Decoy
mice were lower than that from NS or Scr smoke-exposed
mice (Fig. 4). Moreover, the level of MCP-1 and MIP-1α
in lung homogenates was greatly reduced in the decoy
group compared with the NS smoke-exposed group (Fig.
5A), and weakly correlated with total cell number (P =
0.051, ρ = 0.619; P = 0.052, ρ = 0.75, respectively). Instil-
lation of NF-κB decoy ODNs induced a significant
increase in TNF-α protein levels in mice BALF. In contrast,
the level of IL-6 in BALF was not significantly
changed(Fig. 5B).
In addition, PIF and PEF were measured to determine
whether instillation of NF-κB decoy ODNs influences
lung function. As expected, administration of NF-κB
decoys but not scrambled ODNs led to a significant
improvement of PEF (Table 4).
NF-κB decoy ODNs treatment induced pro-MMP-9 in 
BALF, but did not affect pathological changes in small 
airways and alveoli
The concentration of MMP-9 was undetectable in mouse
BALF in our experiment, We therefore measured the levels
of pro-MMP-9 and TIMP-1, which have been shown to be
tissue remodeling-related. Moreover, NF-κB is a critical
transcription factor in the regulation of MMP-9. Of note,
NF-κB decoy ODNs not scrambled ODNs modified the
levels of pro-MMP-9. Additionally, there was no signifi-
cant change in the expression of TIMP-1 (Fig. 6A).
We evaluated alveolar wall destruction and enlargement
of alveolar spaces by morphologic and morphometric
analyses. The level of alveolar wall destruction was deter-
mined by measuring the DI and enlargement of alveolar
spaces, and by quantifying the Lm and the Am. Micro-
scopic analysis of lung tissue sections revealed clearly the
enlarged destroyed alveolar spaces interspersed by appar-
ently normal parenchyma among NS, Decoy and Scr
groups (Fig. 6B). Unexpectedly, no significant difference
was found in Lm, Am, or DI calculated values after 92 days
of smoke exposure (Table 5).
Based on a blinded assessment of the pathology, the
examination of small airways post administration NF-κB
decoy ODNs revealed fibrosis was prominent after admin-
istration NF-κB decoy ODNS in peribronchiolar and
interstitial lung tissue compared to treatment with scram-
ble ODNs while goblet-cell metaplasia scores significantly
reduced compared to NS lung specimens (Table 6).
Discussion
Smoke-induced chronic airway inflammation may be
mediated by overwhelming inflammatory dysregulation
caused by overexpression of not one or several but many
NF-κB regulated genes. We here tested the hypothesis that
blockade of NF-κB transcriptional activity, via phospho-
rothioate-modified decoy ODNs containing the NF-κB
consensus binding site, would improve smoke-induced
chronic airway inflammation and prevent lung dysfunc-
tion in the mouse model system. Our results provided evi-
dence that local administration of decoy through trachea
indeed make a strong decrease of a population of macro-
phages in BALF and alveolar space of smoke-induced
mice. Moreover, NF-κB-regulated chemokines MCP-1 and
MIP-α were strongly repressed in mice BALF after admin-
istration of NF-κB decoy ODNs intratracheally compared
with NS-treated smoke-triggered mice. Conversely, NF-κB
decoy ODNs increased release of TNF-α and pro-MMP-9
in the mice BALF. These data show that NF-κB decoy
ODNs have both repressive and stimulating effects on NF-
κB-regulated inflammatory genes in the mouse model.
We report here that intratracheal administration of decoy
ODNs, but not scrambled control, abrogated NF-κB acti-
vation in whole lung following long-term cigarette expo-
sure; furthermore, we determined that such treatment was
Table 3: Inflammatory cell profile in BALF from NF-κB decoy ODNs (Decoy) and normal saline (NS) treatment in 52 day cigarette 
smoke-exposed mice.
Macrophages(%) Lymphocytes(%) Neutrophils(%)
Decoy 98.62 ± 0.40 0.60 ± 0.47 0.79 ± 0.56
NS 98.94 ± 1.03 0.59 ± 0.70 0.48 ± 0.38
Pr > Chi-Square 0.7728 0.766 0.3094
All data are expressed as means ± STD. The data were analyzed by using the Mann-Whitney U-test in two groups of mice. Statistical significance 
was accepted at P < 0.05. n = 4 per/group.Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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Dot-plots of FITC-labeled NF-κB decoy ODNs and F4/80 double-positive cells in BALF on day 52 in smoke-exposed mice Figure 2
Dot-plots of FITC-labeled NF-κB decoy ODNs and F4/80 double-positive cells in BALF on day 52 in smoke-
exposed mice. NF-κB decoy ODNs were capable of effective entry into alveolar macrophages in BALF. FITC-labeled NF-κB 
decoy ODNs were administered intratracheally on day 52 in smoke-exposed mice. As a negative control, smoke exposed mice 
in 52 days were treated with normal saline (F). After 3 h (A), 24 h (B), 3 days(C) and 7 days (D), macrophages (labeled F4/80) 
from BALF were assessed for FITC positivity using flow cytometry. A population of FITC-labeled NF-κB decoy ODNs and F4/
80 double-positive cells was present in all analysis (R2, higher right quadrant) whereas R1 represented the F4/80-positive, but 
FITC-ODNs negative macrophages. In BALF, cells collected from mice treated with PE-conjugated isotype IgG antibody (E) as 
another negative control. Both of the negative controls showed false positive rate (R1+R2+R4) < 5%, which suggested the flow 
cytometry experiments were not interfered with nonspecific backgrounds. These results were representative of 3 comparable 
experiments.Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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very effective in preventing the development of lung dys-
function and macrophage aggregation in the airway.
Systemic or local injection of "naked" NF-κB decoys may
effectively inhibit NF-κB activation and thereby prevent
inflammation in vivo [25,38]. As reported here, we've
demonstrated that intratracheal administration of
"naked"NF-κB decoys with modified phosphorothioate
backbones resulted in reduced NF-κB activation, while no
effect was observed after scrambled ODN administration.
The decoy ODNs used in this study were phosphorothio-
ated and therefore resistant to degradation. Although we
cannot exclude that the decoy ODNs were damaged
through smoke exposure, there is good evidence that 24 h
after intravenous injection at least 50% of phosphoratio-
ated ODN in the lung were intact [39]. We have previ-
ously shown that NF-κB activation slightly increased
compared to air-exposure mice in a model of subacute
inflammation [27]. Here, we demonstrate that long-term
smoke exposure in mice enhanced NF-κB activity in the
nuclear extracts of lung tissue. The success in vivo transfer
of a sufficient quantity of NF-κB decoy ODN into lungs
was confirmed by the gel shift assay. These results encour-
aged us to study the potential of NF-κB decoy ODNs for
pulmonary smoke-induced chronic airway inflammation
by in vivo via intratracheal administration.
1. Intratracheal delivery of NF-κB decoy ODNs reduced 
macrophage influx and prevented lung dysfunction in 
smoking mice
Many of the genes implicated in smoke-induced chronic
airway inflammation contain NF-κB binding sites in the
promoter/enhancer region (i.e., cytokines, chemokines
and proteases) [1-4]. Of particular clinical relevance, NF-
κB binding activity has been reported to increase in smok-
ers and is correlated with lung function [15].
NF-κB decoy ODNs attenuated macrophage aggregation in smoke-induced chronic inflammation on day 92 Figure 3
NF-κB decoy ODNs attenuated macrophage aggregation in smoke-induced chronic inflammation on day 92. 
(A) Alveolar macrophages (arrows) are largely observed in the lung parenchyma of smoke-exposed mice on day 92 in both 
normal saline-treated smoke-induced mice (NS) and scrambled ODNs-treated smoke-induced mice (Scr), but not in NF-κB 
decoy ODNs administered mice on day 92 of smoke exposure (Original magnification 400×), Bar = 50 μm. (B) Quantitative 
measurement of intra-alveolar macrophages, expressed as macrophages/mm2 (mean ± STD, n = 8/group). There was clear 
decrease of macrophage numbers in Decoy mice compared with NS and Scr group. Symbols delineate statistical significance 
compared to NS mice (*, P < 0.05) and Scr mice (#, P < 0.05). NS: normal saline-treated smoke-induced mice; Decoy: NF-κB 
decoy ODNs-treated smoke-induced mice; Scr: scrambled ODNs-treated smoke-induced mice.Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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In our study, there was no significant increase in the influx
of neutrophils following 92 days smoke exposure, neither
in BALF nor lung parenchyma. This result agreed with
some previous studies, which also have shown that the
inflammatory cell type is cigarette dose-dependent [40]
and related with smoking history in COPD patients [41].
Macrophages have a potential role in the pathogenesis of
COPD which has several important functions such as
phagocytosis[42], activating the adaptive host
response[43]. The alveolar macrophage products include
cytokines and chemokines with the capacity of recruiting
other inflammatory cells to the lungs [44]. Furthermore,
there is a positive association between macrophage num-
bers in the alveolar walls and the presence of mild-to-
moderate emphysema as well as the degree in small air-
ways disease in patients with COPD [45]. Nuclear locali-
sation of p65 in CD68+ alveolar macrophages rather than
neutrophils confirmed the presence of activated NF-κB in
lung parenchyma macrophages of patients with stable
COPD [46]. Therefore, we underline the importance of
studying NF-κB activity in alveolar macrophages in our
research. As expected, the macrophage counts in the BALF
were reduced and paradoxically decreased in the alveolar
regions as assessed by quantificational analysis. Although
cigarette smoke can modify matrix proteins, resulting in
macrophage activation and adherence in the alveolar
spaces together with decrease on alveolar macrophage
population in the BALF [47], we can rule out the effect of
cigarette smoke on the population of macrophages by
comparing NF-κB decoys group to NS group.
It is now clear that macrophage populations can be distin-
guished based on their surface antigen expression, and
functional activity. One population is termed the "inflam-
matory" monocyte/macrophage population and preferen-
tially traffic to sites of inflammation [48]. This function
Treatment with NF-κB decoy ODNs markedly attenuated  the number of airway inflammatory cells in smoke-induced  chronic airway inflammation on day 92 Figure 4
Treatment with NF-κB decoy ODNs markedly atten-
uated the number of airway inflammatory cells in 
smoke-induced chronic airway inflammation on day 
92. Total and differential cell counts were performed on the 
collected BALF. Data were expressed as mean ± STD (n = 8/
group). Symbols delineate statistical significance compared to 
NS mice (*, P < 0.05) and Scr mice (#, P < 0.05). NS: normal 
saline-treated smoke-induced mice; Decoy: NF-κB decoy 
ODNs-treated smoke-induced mice; Scr: scrambled ODNs-
treated smoke-induced mice.
Lung inflammation at 92 days smoke-exposure after treat- ment with normal saline (NS), NF-κB decoy ODNs (Decoy)  or scrambled ODNs (Scr) Figure 5
Lung inflammation at 92 days smoke-exposure after 
treatment with normal saline (NS), NF-κB decoy 
ODNs (Decoy) or scrambled ODNs (Scr). NF-κB 
decoy ODNs inhibited MIP-1α and MCP-1 but not IL-6. The 
level of TNF-α in BALF was increased in Decoy group, com-
pared with the level of that in NS and Scr group. Cytokine 
levels were determined by ELISA and were presented as 
mean ± STD (n = 7–8/group). Symbols delineate statistical 
significance compared to NS mice (*, P < 0.05) and Scr mice 
(#, P < 0.05). NS: normal saline-treated smoke-induced mice; 
Decoy: NF-κB decoy ODNs-treated smoke-induced mice; 
Scr: scrambled ODNs-treated smoke-induced mice.
Table 4: Respiratory function in cigarette smoke-exposed mouse 
groups on day 92.
Treatment PIF(L/S) PEF(L/S)
NS 1.46 ± 0.23 3.69 ± 0.45*
Decoy 1.83 ± 0.34 5.46 ± 0.44
Scr 1.62 ± 0.28 3.79 ± 0.21#
Data were expressed as mean ± STD. PIF: peak inspiratory flow PEF: 
peak expiratory flow. NS: normal saline-treated smoke-exposed mice; 
Decoy: NF-κB decoy ODNs-treated smoke-exposed mice; Scr: 
scrambled ODNs-treated smoke-exposed mice. *P < 0.05 for Decoy 
mice compared with NS mice, # P < 0.05 for Decoy mice compared 
with Scr mice. n = 8/per groupRespiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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difference may explain transfection efficiency was not
over 50%.
As a result of NF-κB inhibition in mouse lung, MIP-1α
and MCP-1 expression in lung was markedly reduced in
the airways of decoy-treated mice as compared to NS-
treated controls, whereas there was no significant decrease
in scramble group compared with NS-treated controls.
This result suggested that the inhibition was from NF-κB
decoy but not double stranded oligodeoxynucleotides.
Prior studies have identified an important role for CC-
chemokines such as MIP-1α in macrophage accumulation
in the lungs of smokers with severe airflow limitation
[49]. It is reasonable to speculate that reduced macro-
phage recruitment in the airways and alveolar space may
be involved in MIP-1α and MCP-1 attenuation or other
chemoattractants are involved in macrophage recruitment
in this model.
The release of pro-inflammatory mediators might play an
important role in long-term smoke-triggered lung inflam-
mation. NF-κB theoretically regulates the secretion of
TNF-α and IL-6. However, our data showed administra-
tion of NF-κB decoy ODNs did not alter IL-6 levels in lung
BALF when compared with scrambled ODNs. Several
explanations may account for these differences. Firstly,
The effect of administration NF-κB decoy ODNs on the structure of pulmonary parenchyma and the expression of pro-MMP- 9 or TIMP-1 in the long-term smoke-induced mice Figure 6
The effect of administration NF-κB decoy ODNs on the structure of pulmonary parenchyma and the expres-
sion of pro-MMP-9 or TIMP-1 in the long-term smoke-induced mice. (A)NF-κB decoy ODNs significantly induced 
high levels of pro-MMP-9 but not TIMP-1 in the BALF of mice. Data were expressed as mean ± STD (n = 8). Symbols delineate 
statistical significance compared to NS mice (*, P < 0.05) and Scr mice (#, P < 0.05). (B) Lung parenchyma from NS, Decoy or 
Scramble-treated smoke-exposed mice at 92 days. Mice were exposed to smoke for 92 days, then they were killed 1 day after 
the last exposure and their lungs processed for light microscopy with haematoxylin-eosin staining. The lesion was character-
ized by disseminated foci of airspace destruction interspersed by apparently normal parenchyma. Original magnification 100×, 
Bar = 200 μm. NS: normal saline-treated smoke-induced mice; Decoy: decoy NF-κB ODNs-treated smoke-induced mice; Scr: 
scrambled ODNs-treated smoke-induced mice. n = 8.
Table 5: Lung Morphologic analysis of mice on 92 days of 
persistent smoke exposure.
Treatment Lm(μm) Am(μm2)D I
NS 46.05 ± 6.71 1019.71 ± 95.62 42.89 ± 9.19
Decoy 45.07 ± 8.23 1137.15 ± 246.28 48.73 ± 15.87
Scr 41.48 ± 4.51 1231.02 ± 139.88 44.54 ± 11.70
Pr > Chi-Square 0.4573 0.0643 0.4712
Data were analyzed by Nonparametric Mann-Whitney U-test and 
expressed as mean ± STD. Lm: linear intercept; Am: mean alveolar 
surface; DI: destructive index; NS: normal saline-treated smoke-
exposed mice; Decoy: decoy NF-κB ODNs-treated smoke-exposed 
mice; Scr: scrambled ODNs-treated smoke-exposed mice. n = 8Respiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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both of these pro-inflammatory cytokines are produced
by a variety of cells types, including macrophages and epi-
thelial cells. NF-κB decoys might not selectively enter into
epithelial cells [25]. In addition, IL-6 release is both NF-
κB and IKK (inhibitor of κB kinase) 2-dependent in
human pulmonary epithelial cells in vitro [50]. Interest-
ingly, in rat asthma model, IκB kinase-2 inhibitor cause
significant dose-related and time-dependent inhibition of
TNF-α [51]. This inhibition of κB were not studied in this
current study and therefore we can not rule out if any
effects of the compound are due to IκB regulation of NF-
κB pathways.
With regard to TNF-α production, our results showed
higher expression in NF-κB decoy ODNs-treated smoke
induced mice compared with NS or Scr-treated control
mice. The possible explanations for this result may be the
relationship between MCP-1 and the inflammatory medi-
ators [52,53]. In addition, there is a diversity in the mech-
anisms of NF-κB-regulated inflammatory genes, which
could explain the reduction in gene expression selectively
for MCP-1 and MIP-1α, but not for TNF-α and IL-6 in
response to NF-κB decoy ODNs administration. Interest-
ingly, one of conserved NF-κB binding sites in IL-6 gene
contained high-affinity AP-1-binding sites, suggesting that
the response of some NF-κB dependent genes may be
modified by adjacent transcription factor regulatory sites.
However, for TNF-α, AP-1 binding sites did not exist in
conserved NF-κB binding sites [54]. More work will be
required to understand NF-κB and other transcription fac-
tors in our model and their regulation function in target
inflammatory genes.
As expected, administration of NF-κB decoy ODNs pre-
vented the development of airway dysfunction in our
study. Previous study showed that both alveolar macro-
phage (Ams) counts and MIP-1α levels in BALF were neg-
atively correlated with FEV (1.0% pred) [55]. This
suggested that macrophages play an important role in
smoking related airflow obstruction. Consistent with
above results, the lower level of MIP-1α in BALF may
cause macrophage influx reduced in the airways and lung
parenchyma, and alleviate airway limitation following
decoy treatment.
2. Intratracheal delivery of NF-κB decoy ODNs did not 
prevent pathological changes in small airways and alveolar 
space in smoking mice
A crucial pathologic feature of COPD is airway inflamma-
tion and remodeling. This process primarily occurs at the
level of the small airways, defined as bronchioles that are
less than 2 mm in diameter in human being. Niewoehner
and colleagues indicated that early structural changes in
the small airways developed before the diagnosis of
COPD was established [23]. We therefore focused on
small airways fibrosis differences among the three groups.
However, the results were unexpected. There was striking
changes in fibrosis and goblet-cell metaplasia reflecting
strong function of NF-κB decoy ODNs for tissue structure
abnormality.
The treatment outcomes we obtained can be associated
with increased expression of pro-MMP-9 and/or TNF-α
expression in BALF after treatment with NF-κB decoy
ODNs. The increase on MMP-9 profile seems consistent
with fibrosis pathological score in small airways in our
study. A similar role of MMP-9 has been reported that
transgenic MMP-9 expression induces adult-onset emphy-
sema in mice [56]. Despite TIMP-1 is thought to be impor-
tant in the airway repair and remodeling processes [57,58]
and one of regulators of MMP-9[59], its profile remained
unchanged in our study. A plausible explanation for the
observed effect in MMP-9 levels in BAL fluid among NF-
κB decoy ODNs treatment groups is the presence of mul-
tiple transcription factor consensus binding motifs in the
MMP-9 promoter, including NF-κB, SP-1, AP-1 and each
of their binding sites are indispensable for PMA-induced
MMP-9 gene transcription in HeLa cells [60]. Although
our data demonstrated that there was unaltered in AP-1
activity that are known to promote MMP expression and a
combination of supershift, RNA interference and overex-
pression experiments implicated AP-1 family member
Fra-1 in the regulation of MMP-1 expression. It is unclear
which transcription factor plays a central regulatory role
in MMP-9 expression in vivo post cigarette exposure, or
whether multiple transcription factors lead to a coordi-
nated response of MMP-9 expression [61]. Gene transcrip-
tion is also reliant on the modification of core histone
proteins, which regulate genome accessibility to transcrip-
tion factors and cofactors [62].
Table 6: Mean Group Score ± STD for Each Pathological Variable on 92 days of persistent smoke exposure.
Group Goblet-Cell Metaplasia Inflammatory-Cell Infiltration Fibrosis Muscle
NS 9.17 ± 5.05 5.50 ± 1.48 6.42 ± 2.15 5.58 ± 1.88
Decoy 3.70 ± 2.54* 6.79 ± 4.00 9.71 ± 4.27# 5.08 ± 2.42
Scr 5.30 ± 2.19 4.5 ± 1.58 4.68 ± 2.26 4.94 ± 2.59
Data were analyzed by Nonparametric Mann-Whitney U-test and expressed as mean ± STD. NS: normal saline-treated smoke-exposed mice; 
Decoy: decoy NF-κB ODNs-treated smoke-exposed mice; Scr: scrambled ODNs-treated smoke-exposed mice. *P < 0.05 for Decoy mice 
compared with NS mice, # P < 0.05 for Decoy mice compared with Scr mice. n = 5–7/per groupRespiratory Research 2009, 10:79 http://respiratory-research.com/content/10/1/79
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MMPs are both effectors and regulators of inflammation.
Pro-inflammatory stimuli such as TNF-α and IL-1β also
increased MMP-9 production in human monocytes
[63]while there were examples of MMP-mediated release
or activation of cytokines including TNF-α [64]. Together,
this suggests the intersection between the chemokine and
MMP networks is broad with potentially important bio-
logical consequences. In our results, we observed the ele-
vation of pro-MMP-9 profile in concomitance with higher
level of TNF-α and lower expression of MCP-1 and MIP-
1α post treatment with NF-κB decoy ODNs. It is possible
that cytokines and MMPs networks play a key role in
orchestrating the inflammation via non-dependent NF-κB
pathway in smoke-induced mice model. Other studies
have documented possible effects of TNF-α on the devel-
opment of pulmonary fibrosis through chronic lung
inflammation and activation of the elastolytic enzymes
[65]. In particular, NF-κB site is indispensable for the sup-
pressive activity of TGF-β in the regulation of MMP-9 tran-
scription[66].
Conclusion
We reported here that local NF-κB inhibition was associ-
ated with attenuated MIP-1α and MCP-1 expression
simultaneously, macrophage influx in the airway and
lung parenchyma, and marked improvement in respira-
tory function of mice in response to long-term smoke
exposure. Our studies suggest that inhibitors of NF-κB
may offer promise as a therapeutic approach for the
improvement of smoke-triggered pulmonary dysfunction.
Furthermore, our pathological analysis of the macro-
phages reduction in lungs of mice and macrophages
recruitment-related cytokines decrease also provides use-
ful information about NF-κB decoy ODNs for a model of
experimental smoke-induced chronic inflammation.
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